NCT04215432

Brief Summary

The objective of this study was to perform the first clinical trial to evaluate the effectiveness of propolis extract, nanovitamin C and nanovitamin E gel as adjuvant to mechanical debridement in clinical and microbiological parameters of implants with peri-implant mucositis

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2018

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 25, 2019

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 21, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 21, 2019

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 2, 2020

Completed
Last Updated

January 2, 2020

Status Verified

December 1, 2019

Enrollment Period

1.5 years

First QC Date

December 21, 2019

Last Update Submit

December 31, 2019

Conditions

Keywords

dental implantsperi-implant mucositstoothpastepropolisnanovitamin

Outcome Measures

Primary Outcomes (1)

  • Changes in bleeding on probing

    It was present when it appeared bleeding at the gingival margin after recording probing depths at six sites in each implant. Modified bleeding index was also collected.

    baseline and 1-month follow-up

Secondary Outcomes (3)

  • Changes in probing depth

    baseline and 1-month follow-up

  • Changes in plaque index

    baseline and 1-month follow-up

  • Changes in microbilogical sample

    baseline and 1-month follow-up

Study Arms (2)

Test group

EXPERIMENTAL

Gel contained in tubes with the same appearance (30g), identical in colour, flavour and density, with the following components: Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethylene glycol, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate, Deionized Water, Propolis Extract (2%), Ascorbic Acid (0.2%) and Tocopherol Acetate (0.2%).

Device: Gel containing propolis extract, nanovitamin C and nanovitamin E

Placebo group

PLACEBO COMPARATOR

Gel contained in tubes with the same appearance (30g), identical in colour, flavour and density, with the following components: Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethylene glycol, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate, Deionized Water and E155/151 coloring.

Device: Placebo

Interventions

The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis. during 1 month.

Test group
PlaceboDEVICE

The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis.

Placebo group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • cooperative adult patients,
  • with one or more implants with peri-implant mucositis, and
  • presenting at least 18 months of functional loading.

You may not qualify if:

  • refuse to participate in the study,
  • patients who had implants with peri-implantitis (BOP and/or suppuration together with progressive radiographic marginal bone loss),
  • patients with uncontrolled periodontitis (presence of nine or more sites with PD ≥ 5 mm and with full-mouth bleeding score (FMBS) \> 25%),
  • systemic diseases or conditions that could alter the results of the study (diabetes mellitus, immunosuppression, infectious diseases, rheumatoid disease, history of bisphosphonate treatment, radiotherapy, chemotherapy, etc.),
  • patients who had taken local and/or systemic antibiotics less than 2 months ago,
  • pregnant or breastfeeding women, and
  • patients with history of allergies to the test and/or placebo components administered.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidad Complutense de Madrid

Madrid, 28005, Spain

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

December 21, 2019

First Posted

January 2, 2020

Study Start

May 1, 2018

Primary Completion

October 25, 2019

Study Completion

December 21, 2019

Last Updated

January 2, 2020

Record last verified: 2019-12

Locations